Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules

Clinical Cancer Research

Volumn 7, Issue 9, 2001, Pages 2923-2930

  Aherne, G W ^a   Hardcastle, A ^a   Ward, E ^a   Dobinson, D ^a   Crompton, T ^a   Valenti, M ^a   Brunton, L ^a   Jackman, A L ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLEVITREXED; RALTITREXED; THYMIDYLATE SYNTHASE INHIBITOR;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; DNA SYNTHESIS; DRUG ELIMINATION; DRUG TISSUE LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; DEOXYRIBONUCLEOTIDES; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; INFUSION PUMPS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; LYMPHOMA; MICE; MICE, INBRED DBA; NUCLEOSIDE-PHOSPHATE KINASE; QUINAZOLINES; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0034812173     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. The new generation of thymidylate synthase inhibitors in clinical study: Oncologic, endocrine and metabolic
2. Cell cycle control processes determine cytostasis or cytotoxicity in thymineless death of colon cancer cells
3. The role of uracil misincorporation in thymineless death
4. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: A water soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase
5. Phase 1 study of ZD9331: A novel thymidylate synthase (TS) inhibitor
6. Phase I trial of ZD9331, a non-polyglutamatable thymidylate synthase (TS) inhibitor given as a five-day continuous infusion
7. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: New agent for clinical study
8. ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer
9. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of Tomudex (ZD1694) and a non-polyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukemia cells
10. The measurement of deoxynucleotide pools by radioimmunoassay
11. Use of murine L5178Y lymphoma thymidine kinase mutants for in vitro and in vivo antitumor efficacy evaluation of novel thymidylate synthase inhibitors
12. ZD9331: Preclinical and clinical studies
13. The renal effects of the water soluble non-folylpolyglutamate synthetase dependent thymidylate synthase inhibitor, ZD9331, in mice
14. Development of an enzyme-linked immunosorbent assay for isoproturon in water
15. 10-propargyl-5,8-dideazafolic acid (ICI 19583)
16. 10-propargyl-5,8-dideazafolic acid (ICI 19583)
17. Development and application of a radioimmunoassay for methotrexate
18. Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models
19. A sensitive and specific radioimmunoassay for LY309887, a potent inhibitor of glycinamide ribonucleotide formyltransferase
20. The in vivo metabolic stability of dipeptide analogues of the quinazoline antifolate, ICI 198583, in mice
21. Preclinical pharmacology of CB30900, a novel dipeptide inhibitor of thymidylate synthase, in mice
22. Balb/c mice as a preclinical model for raltitrexed-induced gastrointestinal toxicity
23. Cell cycle effects of antifolate antimetabolites: Implications for cytotoxicity and cytostasis
24. Cell cycle effects of CB30865, a lipophilic quinazoline-based analogue ICI 198583 with an undefined mechanism of action
25. DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells
26. Mechanisms of cell death following thymidylate synthase inhibition: 2′deoxyuridine-5′-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole
27. Resistance to fluorodeoxyuridine-induced DNA damage and cytotoxicity correlates with an elevation of deoxyuridine triphosphatase activity and failure to accumulate deoxyuridine triphosphate
28. The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition
29. Comparison of the cellular pharmacology of ZD9331 in L5178Y TK+/- and TK-/- mouse lymphoma cell lines
30. Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331
31. Overview of recent topics in clinical pharmacology of anticancer agents
32. Plasma 2′deoxyuridine (dUrd) as a surrogate marker of thymidylate synthase (TS) inhibition in patients in Phase I clinical trials of the TS inhibitor ZD9331